Dr. Greg Rigdon is Senior Vice President of Scientific Affairs at Arrivo Bioventures. Greg’s drug development experience includes discovery through phase 4 clinical trials and his regulatory experience includes IND and NDA filings. He has over 30 years experience in the industry from running a neuropharmacology laboratory at Burroughs Wellcome to managing clinical development teams at Glazo Wellcome and Icagen to serving as a clinical pharmacology consultant. He has experience in multiple therapeutic areas: psychiatry, neurology, sickle cell disease, preeclampsia and multiple GI indications.  In his current  role he manages the nonclinical aspects of drug development, interacts with regulatory authorities and designs clinical trials. 
Greg has authored/co-authored over 30 journal articles in pharmacology, neuroscience and clinical research. He is also an inventor with multiple  patents and has guest lectured at the University of North Carolina at Chapel Hill, North Carolina State University and Campbell University. Greg earned his Ph.D. in Pharmacology from Texas Tech University Health Sciences Center in 1985.

Dr. Wargin has over 20 years of experience as a pharmacokineticist, having worked with 60+ small and large pharmaceutical companies developing drugs in several therapeutic areas including CNS, oncology, anti-viral, cardiovascular and metabolic disease. In this context, he has worked in nonclinical drug development including in-vitro and in-vivo metabolism and pharmacokinetics. During Phase 1 development, he participated in design and implementation of clinical pharmacology studies from first time in humans to bioequivalence studies for new formulations post-approval, partnered with CROs for protocol development, review and study conduct, and provided pharmacokinetic and PK/PD data analysis of data and report writing. Dr. Wargin has written several nonclinical ADME/PK sections of IND submissions and clinical pharmacology sections of NDAs in CTD format and has participated in 10+ pre-IND meetings in various therapeutic areas.

Dr. Vatsalya is an Assistant Professor of Medicine in the Department of Medicine at the University of Louisville in the Division of Gastroenterology, Hepatology, and Nutrition. He is also affiliated with the VA Robley Rex Medical Center as a clinical scientist. Dr. Vatsalya is trained as a physician, but his primary role is research and support for patients with their mental health conditions. He is an addiction specialist, licensed in addiction and mental health in Kentucky. He is a PI on medication trials on AUD, funded both institutionally and federally, including the National Institutes of Health. During his fellowship, he developed and validated the food-alcohol task, which is used widely in human neural-mechanistic-treatment studies (disease, and non-treatment-seeking cohorts). He has developed novel clinical paradigms to study treatment efficacy in various patient populations. Dr. Vatsalya has a novel drug registered with the US Patent and Trademark Office for the treatment of AUD-ALD as a dual-target therapy, licensing efforts and phase I preparation have been initiated. Notably, he was also in a group of addiction investigators that developed the WHO's ICD 11 code for alcohol hangover conditions. He has an independent clinical research lab and has several clinical publications in high-impact, prestigious-ranking national and international journals. He mentors several clinical trainees and clinical and non-clinical students.

Michael J. Fossler, Jr is Executive Consultant and Vice-President, Strategic Consulting at Cytel. He received PharmD (1992) and PhD (1995) degrees from the Univ of Maryland. From 1995 to 2000, Dr. Fossler was employed by the FDA as a clinical pharmacology reviewer in the Div of Metabolic and Endocrine Drug Products.  In 1998, he was promoted to Senior Reviewer and joined the Pharmacometrics group at FDA, where he was responsible for reviewing and performing population PK/PD analyses. He left the Agency in 2000 and joined the Clinical Pharmacokinetics Group at DuPont Pharmaceuticals, where he had major responsibility for PK/PD analyses in the cardiovascular and anti-inflammatory areas. In November, 2001, he joined GlaxoSmithKline, where he continued to work in the cardiovascular area, and eventually headed a group of nine pharmacometrics scientists. He left GSK in 2015 to join Trevena Inc, a late-stage small biotech company, where he led clinical pharmacology, clinical development, biostatistics, programming and data management.  He assumed his present role at Cytel in April 2022, where he provides strategic consulting services in the areas of clinical pharmacology and pharmacometrics. Dr. Fossler is a Fellow of the American Foundation for Pharmaceutical Education, a Fellow of the American College of Clinical Pharmacology, a past President of the College and is an Honorary Regent and former Councilor to the President.  He holds an adjunct faculty appointment at the Univ of North Texas where he teaches in the school’s Pharmacometrics program. He has been quoted in the media (Wall St. Journal, NPR) on issues related to medicines and drug development.

Craig Hendrix, MD, has been a Member of ACCP since 2018 and became a Fellow in 2019. He has served the society in various capacities, including current service as Treasurer and the Executive Committee since September 2024 and as a member of the Board of Regents since 2020. He currently chairs the Conflict of Interest Work Group and previously chaired the Credentials Committee (2021-2022), Special Interest Group Task Force (2022-2023) and Finance Committee (2022-2024). He was a Faculty Speaker and/or Symposia leader at the ACCP Annual Meeting in 2016, 2017, 2019, 2023 and 2024 as well as serving several years as an Abstract Reviewer. He received the ACCP Distinguished Investigator Award in 2018. 

Dr. Hendrix is currently Professor Emeritus at the Johns Hopkins Univ and Senior Scientist at Oak Crest Institute of Science in Monrovia, CA. In 30 years on the Hopkins medical school faculty, he served the past decade as the Wellcome Professor and Director, Div of Clinical Pharmacology (2015-2025), Director of the Hopkins T32-funded Clinical Pharmacology Training Program and Director of their outpatient Phase I Drug Development Unit. He obtained his baccalaureate degree at MIT and doctorate in medicine at Georgetown Univ after which he went to The Johns Hopkins Hosp for housestaff and fellowship training in internal medicine, infectious diseases and clinical pharmacology. He served 13 years in the US Air Force, including deployment for Desert Storm. 

His primary research focus is the clinical pharmacology of HIV pre-exposure prophylaxis and he has served as Principal Investigator of over 120 phase I clinical studies and principal pharmacologist for over 80 multi-center clinical trials. He has also served on a National Academy of Medicine Advisory Panel, the CDC Board of Scientific Counselors and several FDA Advisory Committees. He is the current Chairman of the American Board of Clinical Pharmacology. 

Dr. Manjunath Pai is Professor and Chair of Clinical Pharmacy, and Co-Director of the Pharmacokinetics Core at the Univ of Michigan. His research focus is optimal drug dose selection in specific populations such as patients with obesity and abnormal kidney function. His group repurposes existing CT scans to generate body composition and imaging biomarkers predictive of clinical pharmacology, an approach coined as “pharmacomorphomics”. He earned his PharmD from the Univ of Texas Health Sciences Ctr in San Antonio, Texas, a residency at Bassett Healthcare in Cooperstown, New York and a pharmacokinetics fellowship at the Univ of Illinois at Chicago. Dr. Pai has received multiple honors for his scientific contributions including the Russell R. Miller Award for sustained and outstanding contributions to the clinical pharmacology literature.

Dr Suneet Shukla is a Director (Clinical Pharmacology) at Boehringer Ingelheim Pharmaceuticals, USA where he leads global Clinical Pharmacology programs in oncology, inflammation, and cardio renal metabolism therapeutic areas for both large and small molecules.

Dr Suneet Shukla is a pharmacist by educational training with a Ph.D. in molecular pharmacology studying drug transporters, their role in fungal infections and drug resistance. After graduation, he continued to pursue his research interest in drug transporters for over 10 years at the National Cancer Institute (NCI), NIH where he completed his postdoctoral training in the Laboratory of Cell Biology and was later appointed as Staff Scientist. He then joined US Food and Drug Administration and has worked in the Offices of New Drug Products, Generic Drugs and Clinical Pharmacology and acted as ophthalmology team lead where his responsibilities included the review of INDs, NDAs, ANDAs, and other regulatory submissions from a biopharmaceutics, bioequivalence and clinical pharmacology perspective.

Suneet has published several highly cited research and review articles, received patents, and awards from NIH and FDA. He has served on panels evaluating research grants submitted to NIH and FDA, mentored several undergraduate, graduate, and post-doctoral trainees. He is currently serving as member of American College of Clinical Pharmacology Public Policy Committee and has served as the lead instructor of the medical pharmacology course at the Foundation for Advanced Education in the Sciences (FAES) Graduate School, NIH.

David J. Greenblatt, M.D.

Louis Lasagna Endowed Professor, Tufts University School of Medicine.

             A native of Newton, Massachusetts, Dr. Greenblatt is a Magna Cum Laude graduate of Amherst College (1966). He graduated from Harvard Medical School in 1970, then trained in internal medicine at the Montefiore Hospital, New York City (1970-1971), and on the Harvard Medical Service at Boston City Hospital (1971-1972). Following a Fellowship in Clinical Pharmacology at Massachusetts General Hospital, under the mentorship of Dr. Jan Koch-Weser (1972-1974), he stayed on to head their Clinical Pharmacology Unit (1975-1979).

             Dr. Greenblatt has been on the Faculty of Tufts University School of Medicine (TUSM) and the Staff of Tufts Medical Center (TMC) since 1979. He is a senior faculty member in the Graduate Program in Pharmacology & Drug Development, and has previously served as Chair of the Department of Pharmacology and Experimental Therapeutics at TUSM, Program Director and Associate Program Director of the institution’s Clinical/Translational Research Center, and Chair of the Institutional Review Board. He has received many awards and honors over his career, including the Distinguished Investigator Award from the American College of Clinical Pharmacology, and the Oscar B. Hunter Career Achievement Award from the American Society for Clinical Pharmacology and Therapeutics

Joseph D. Ma, PharmD, FCP is Professor in the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences, Univ of California San Diego.  He is also the faculty director of the Drug Development and Product Management Master’s Program at UC San Diego. He received his pharmacy degree from Univ of California San Francisco and completed a clinical pharmacology fellowship at Bassett Healthcare, Cooperstown, NY.  His research interests are evaluating in vivo drug metabolizing enzyme activity in the context of drug-drug interactions and opioid pharmacokinetic variability.  His current clinical practice is the Doris A. Howell Pain and Palliative Care Service at the Univ of California San Diego Moores Cancer Center. Under a collaborative practice agreement he is able to initiate, stop, and/or adjust therapy for the management of pain and other physical symptoms associated with cancer and/or chemotherapy. 

Kacey Anderson, PhD, is Director of Clinical Pharmacology at Terns Pharmaceuticals. Prior to Terns, Dr. Anderson was a Director of Clinical Pharmacology at EQRx International and prior to that she was at Gilead Sciences in clinical pharmacology. Dr. Anderson has worked on programs from early stage (IND filing and development plan) through approval, including being primary author on multiple m2.7.2’s in both US and ex-US submissions in inflammation and oncology disease areas. She has more than eight years of industry experience which includes designing and leading a variety of Phase 1 studies as well as supporting Phase 2 and Phase 3 studies. Dr. Anderson earned her PhD in Pharmaceutical Sciences from the University of Pittsburgh and holds a Bachelor of Science in Chemistry from St. Lawrence University. She is a Fellow of the American College of Clinical Pharmacology (ACCP) and has served on numerous committees and initiatives within ACCP. 

Navin Goyal is a Senior Director and Therapy Area Lead in the Clinical Pharmacology and Pharmacometrics (CPP) Group at Janssen Pharmaceuticals, New Jersey. Dr. Goyal joined ACCP as a student in 2007, has been a Fellow since 2016, currently serves on the Board of Regents and is Treasurer for ACCP. He was the 2021 ACCP Annual Meeting Co-Chair. He has also chaired scientific symposia and presented at previous Annual Meetings.
Dr. Goyal graduated from the Department of Pharmaceutics in College of Pharmacy at University of Florida, Gainesville. After graduation, he worked in the Clinical Pharmacology, Modeling and Simulation group at GSK. At Janssen, Dr. Goyal is the CPP head of cardiovascular, metabolism, retinal, pulmonary hypertension and neuroscience therapy areas. In this role, he is responsible for applying quantitative clinical pharmacology principles and approaches across all phases of drug development spanning from early clinical studies through registration. He has published his research in clinical pharmacology and pharmacometrics across multiple therapy areas including respiratory, CNS, cardiovascular and infectious diseases. Apart from his day job, Dr. Goyal continues to mentor student interns, post-doctoral fellows and scientists within his group at Janssen and through external collaborations.

Zaid Temrikar works as a clinical pharmacologist at Gilead Sciences supporting early and late stage assets within Immunology and Oncology portfolio in Foster City, CA. He completed his PhD from UTHSC in Memphis TN working on PK/PD of anti-infectives. He has held many leadership positions such as part of inaugural ACCP leadership cohort, student president of ISoP and president of AAPS student chapter. He has also been a part of ACCP STEP and ACCP Annual Meeting Program Committee. 

Kacey Anderson, PhD, is Director of Clinical Pharmacology at Terns Pharmaceuticals. Prior to Terns, Dr. Anderson was a Director of Clinical Pharmacology at EQRx International and prior to that she was at Gilead Sciences in clinical pharmacology. Dr. Anderson has worked on programs from early stage (IND filing and development plan) through approval, including being primary author on multiple m2.7.2’s in both US and ex-US submissions in inflammation and oncology disease areas. She has more than eight years of industry experience which includes designing and leading a variety of Phase 1 studies as well as supporting Phase 2 and Phase 3 studies. Dr. Anderson earned her PhD in Pharmaceutical Sciences from the University of Pittsburgh and holds a Bachelor of Science in Chemistry from St. Lawrence University. She is a Fellow of the American College of Clinical Pharmacology (ACCP) and has served on numerous committees and initiatives within ACCP. 

Navin Goyal is a Senior Director and Therapy Area Lead in the Clinical Pharmacology and Pharmacometrics (CPP) Group at Janssen Pharmaceuticals, New Jersey. Dr. Goyal joined ACCP as a student in 2007, has been a Fellow since 2016, currently serves on the Board of Regents and is Treasurer for ACCP. He was the 2021 ACCP Annual Meeting Co-Chair. He has also chaired scientific symposia and presented at previous Annual Meetings.
Dr. Goyal graduated from the Department of Pharmaceutics in College of Pharmacy at University of Florida, Gainesville. After graduation, he worked in the Clinical Pharmacology, Modeling and Simulation group at GSK. At Janssen, Dr. Goyal is the CPP head of cardiovascular, metabolism, retinal, pulmonary hypertension and neuroscience therapy areas. In this role, he is responsible for applying quantitative clinical pharmacology principles and approaches across all phases of drug development spanning from early clinical studies through registration. He has published his research in clinical pharmacology and pharmacometrics across multiple therapy areas including respiratory, CNS, cardiovascular and infectious diseases. Apart from his day job, Dr. Goyal continues to mentor student interns, post-doctoral fellows and scientists within his group at Janssen and through external collaborations.

Zaid Temrikar works as a clinical pharmacologist at Gilead Sciences supporting early and late stage assets within Immunology and Oncology portfolio in Foster City, CA. He completed his PhD from UTHSC in Memphis TN working on PK/PD of anti-infectives. He has held many leadership positions such as part of inaugural ACCP leadership cohort, student president of ISoP and president of AAPS student chapter. He has also been a part of ACCP STEP and ACCP Annual Meeting Program Committee.